Biomarkers

Dupuytren and Fear of the Unknown

Dupuytren and Fear of the Unknown Boopuytren! Here’s a common Dupuytren script. A person finds something unexplained in their palm. They see a hand surgeon, who tells them “You have Dupuytren disease.” “There’s nothing to do now.” “Come back when you can’t put your palm flat on a tabletop.” First, disappointment: the doctor did …nothing! (and […]

Read more ›
The Importance of Dupuytren Stories
On: Oct 17, 2018
By: Charles Eaton

The story depends on the storyteller. For nearly two centuries, the only narrators of the story of Dupuytren have been doctors and therapists. The public face of Dupuytren was limited either to what was easy to describe (measuring finger angles) or to technical details relevant to surgery. It was a narrow tunnel vision about what […]

Read more ›
Mother’s Day Maps

May is here. Summer is coming! In many countries, Mother’s day is being celebrated this Sunday. It’s a meaningful milestone. Dupuytren Research Group is also marking milestones – on a variety of maps. International Dupuytren Data Bank Enrollment The IDDB is nearing the 3000 enrollee mark: as of today, we have 2996 enrollees. Here is […]

Read more ›
Dupuytren Triggers: 60 second survey
On: Dec 16, 2017
By: Charles Eaton

Dupuytren Triggers Yes, that’s a picture of Roy Roger’s horse, Trigger. You might not have been expecting that. Dupuytren also shows up unexpectedly. People have normal hands, and then they don’t. Many feel the problem came out of nowhere. Others may recall some event happening around the same time as Dupuytren first appeared and conclude […]

Read more ›
How common is Dupuytren Disease?
On: Apr 1, 2017
By: Charles Eaton

How common is Dupuytren disease? The short answer is this:  much more common than you might think. Scroll to the bottom to get the summary numbers. For the long answer, keep reading. The details depend on where you get your data. One set of data comes from a large web-based survey (DiBenedetti 2010). One conclusion […]

Read more ›
Cannabinoids, Dupuytren, and Orphan Drugs
On: Mar 3, 2017
By: Charles Eaton

I was recently asked if medical marijuana might be helpful for Dupuytren disease. The short answer is “No one knows.”. The longer answer is much more interesting. The late effect of Dupuytren disease is Dupuytren contracture. The medical term for the findings in Dupuytren contracture is fibrosis. Sclerosis also means the same thing. If either of […]

Read more ›
Happy Valentine’s Day from Dupuytren Research Group!
On: Feb 14, 2017
By: Charles Eaton

Two Dupuytren stories for this Valentine’s Day. First, Saint Valentine. There were nearly a dozen people called Saint Valentine. Did this one have Dupuytren Contracture? He’s clearly in the high risk demographic – an old Caucasian man. Looks like he’s got it, but we’ll never know. It is important to know that there’s a lot […]

Read more ›
The Future is Coming!

Improving the Future of Dupuytren Care Right now, many people with mild Dupuytren biology do well after surgery or after Xiaflex – because most people have mild to moderate Dupuytren biology. The issue isn’t the patient with mild disease biology who will do well for a long time after any treatment. The issue is those […]

Read more ›
Happy Thanksgiving from the Dupuytren Foundation!

Turkey Day Update! Much has happened since the last Dupuytren Foundation report in July. The International Dupuytren Data Bank (IDDB) averages 100 new enrollees each month. We’re continuing to work out the complicated details of blood testing. If you haven’t enrolled yet, now is the time: http://DupStudy.com. Our international research committee continues to grow. So does […]

Read more ›